Michael Barry, MD
Cardiovascular Disease · Clearwater, FLNPI 1619026770
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (54.6%), food and beverage and education — rather than concentrated in one kind of arrangement. 17 manufacturers reported payments, led by Edwards Lifesciences at 44.3% of the total. 2025 is the largest year on record at $2,293, 2.4 times the $973 reported in 2019.
Across 153 payments — averaging $44.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$3K
- Abbott$2K
- Medtronic$286
- E.r. Squibb & Sons, L.L.C.$208
- Pfizer$204
- Novartis$194
- plus $880 from 11 others
Across 12 payments — averaging $6769.81 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$42K
- Heartflow, Inc.$23K
- AstraZeneca$17K
What the payments were for
- Travel & lodging$3,67855%
- Food & beverage$3,05045%
- Education$30%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 15 | $2,983 |
| Abbott | 26 | $1,977 |
| Medtronic(2 entities) | 10 | $286 |
| E.r. Squibb & Sons, L.L.C. | 26 | $208 |
| Pfizer | 10 | $204 |
| Novartis | 13 | $194 |
| AstraZeneca | 14 | $175 |
| Boston Scientific | 9 | $163 |
| Amgen | 8 | $142 |
| Astellas Pharma US Inc | 3 | $72 |
| Sanofi-aventis U.S. LLC | 3 | $69 |
| Johnson & Johnson | 4 | $63 |
| Boehringer Ingelheim | 3 | $59 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $58 |
| Amarin Pharma, Inc. | 3 | $47 |
| Kowa Pharmaceuticals America, Inc. | 1 | $16 |
| Heartflow, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EVOQUE$1,537
- PASCAL$982
- MitraClip System$334
- Reveal LINQ$138
- Mitra Clip system$111
How this compares
$6,732 in reported general payments places this provider in the 70th percentile of 1,740 cardiovascular disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 444 | $512,448 |
| XareltoRivaroxaban | 184 | $224,616 |
| EntrestoSacubitril/Valsartan | 104 | $154,615 |
| Repatha SureclickEvolocumab | 128 | $111,726 |
| JardianceEmpagliflozin | 52 | $48,639 |
| FarxigaDapagliflozin Propanediol | 41 | $31,314 |
| BrilintaTicagrelor | 14 | $18,515 |
| Metoprolol Succinate | 452 | $6,069 |
| Ezetimibe | 143 | $5,631 |
| Rosuvastatin Calcium | 406 | $4,626 |
| Flecainide Acetate | 102 | $4,581 |
| Amlodipine Besylate | 519 | $4,348 |
| Atorvastatin Calcium | 514 | $4,199 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 20 | $3,629 |
| ClopidogrelClopidogrel Bisulfate | 332 | $3,586 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $204 | $512,448444 claims |
| Johnson & JohnsonXarelto | $63 | $224,616184 claims |
| NovartisEntresto | $194 | $154,615104 claims |
| AstraZenecaFarxiga, Brilinta | $175 | $49,82955 claims |
| Boehringer IngelheimJardiance | $59 | $48,63952 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,740 cardiovascular disease providers in Florida.
Other cardiovascular disease in Clearwater
- Kevin MakatiLutz$1.6M
- Hiram BezerraTampa$698K
- William OneillNaples$637K
- Theodore FeldmanMiami$637K
- John Gerald CantoLakeland$588K
- Alan MillerJacksonville$547K
- Seth BaumBoca Raton$517K
- Elliott EliasMiami$497K
- Vijay HaryaniVero Beach$413K
- Neel PatelMaitland$392K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.